SCHEMBL30976372

SCHEMBL30976372

CCn1nc(C(=O)N2CCN(c3ncc(C(F)(F)F)cc3Cl)CC2)c2ccccc2c1=O

nearest known ligand 0.72

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
SMN1; SMN2 Q16637 6/20 0.52
MAPT P10636 5/20 0.52
ALDH1A1 P00352 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
KDM4E B2RXH2 2/20 0.51
NAMPT P43490 1/20 0.51
LMNA P02545 4/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 2/20 0.49
HPGD P15428 1/20 0.49
CHRM4 P08173 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30976361 0.91 KMT2A (0.52) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL30976446 0.90 KMT2A (0.52) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL30976463 0.84 LMNA (0.58) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL30976411 0.81 TP53 (0.56) KMT2AMEN1MAPTALDH1A1NPSR1
SCHEMBL30976292 0.79 ALDH1A1 (0.52) KMT2AMEN1MAPTALDH1A1NPSR1
SCHEMBL30976499 0.77 LMNA (0.56) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL30976325 0.75 LMNA (0.54) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL13012376 0.74 SMN1; SMN2 (0.77) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL1432512 0.73 KMT2A (0.72) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL13930739 0.72 MAPT (0.78) KMT2AMEN1SMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619387-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE Soley Therapeutics, Inc. (US) 2025-09-24 EP disclosed
WO-2024108131-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS, INC. (US) 2024-05-23 WO disclosed